Malaysia
Search
Sign In
Change Password
Points
Sign Out
Extended exposure to proton pump inhibitors (PPIs) may raise mortality risk in individuals with decompensated cirrhosis, according to a Singapore study.
Nivolumab, used in the first-line treatment of patients with advanced hepatocellular carcinoma (HCC), has demonstrated clinically meaningful improvements in overall survival (OS) and response rates vs sorafenib in the phase III CheckMate 459 study, although the improvement in OS did not reach statistical significance.
Pembrolizumab improved progression-free survival (PFS) and overall survival (OS) over best supportive care in patients with advanced hepatocellular carcinoma (HCC), according to the phase III KEYNOTE-240* trial, supporting its role as a treatment option for HCC in the second-line setting.
Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.
The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).
Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress™ (ILC 2019).
Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress™ (ILC 2019).
Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.
